title: [Prostate cancer cell vaccine transfected with 4-1BBL induces anti-tumor immunity in vitro].
abstract: OBJECTIVE
  To explore the anti-tumor immunity in vitro induced by prostate cancer cell vaccine transfected with recombinant adenovirus encoding 4-1BBL in mice.
  
  
  METHODS
  The replication-deficient adenovirus AdEasy-1 system was used to construct recombinant adenovirus Ad-m4-1BBL and Ad-eGFP. The prostate cancer cell RM-1 of mice was transfected with Ad-m4-1BBL and Ad-eGFP, and treated with mitomycin (MMC) to produce TCV, TCV-Ad-eGFP and TCV-Ad-m4-1BBL, followed by co-culture with syngeneic murine spleen cells. Then the cytotoxic activity of the lymphocytes against RM-1 cells was analyzed with CCK-8 solution, and IL-2 and INF-gamma were detected by ELISA.
  
  
  RESULTS
  The 4-1BBL protein was highly expressed in the TCV-Ad-m4-1BBL of the 4-1BBL-transfected mice. TCV-Ad-m4-1BBL significantly increased the expressions of IL-2 ([180.24 +/- 2.22] pg/ml) and INF-gamma ([1512.46 +/- 23.64] pg/ml) as compared with TCV and TCV-Ad-eGFP (P < 0.05), and induced higher RM-1 cell specific cytotoxicity ([34.24 +/- 2.64]%) than the latter two ([9.82 +/- 1.48]%) and ([14.65 +/- 3. 21]%), (P < 0.05). But none of them exhibited significant cytotoxicity against hepatocellular carcinoma Hepal-6.
  
  
  CONCLUSIONS
  The m4-1BBL-expressing prostate cancer cell vaccine can effectively induce anti-tumor immune responses.
authors.affiliation: Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
authors.forename: You-lin
authors.initials: YL
authors.lastname: Kuang
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Weng
authors.forename: Xiu-heng
authors.initials: XH
authors.lastname: Liu
authors.forename: Zhi-yuan
authors.initials: ZY
authors.lastname: Chen
authors.forename: Heng-cheng
authors.initials: HC
authors.lastname: Zhu
authors.forename: Bo-tao
authors.initials: BT
authors.lastname: Jiang
mesh_terms: D053330:4-1BB Ligand / Q000235:genetics* / Q000276:immunology*; D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics* / Q000276:immunology*; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D005260:Female; D007376:Interleukin-2 / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011471:Prostatic Neoplasms; D014162:Transfection
chemical_list: D053330:4-1BB Ligand; D019496:Cancer Vaccines; D007376:Interleukin-2